drugset

drugset / Trial / NCT03291444

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

NCT03291444 ↗

Phase 1 Unknown 30 enrolled Zhujiang Hospital Shenzhen Geno-Immune Medical Institute · collab Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Timeline

Start: 2018-05-05
Primary completion: 2024-12-31
Completion: 2025-06-01

Publications

Tu S, Zhou L, Huang R, Zhou X, Yang J, He Y, Hu Y, Zhang H, Xie X, Li Y. Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. Am J Hematol. 2024 Jul;99(7):1437-1440. doi: 10.1002/ajh.27349. Epub 2024 May 7. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Chimeric antigen receptor T cells	Cell therapy	—	—
Subject	peptide specific dendritic cell	Vaccine	—	Other

Indications